Noël J-M Raynal , Ph.D. , M.Sc.
    Noël J-M Raynal
    Research Axis
    Immune Diseases and Cancer
    Research Theme
    Pharmacology and pharmacogenetics

    514 345-4931 #6763



    • Assistant professor, Department of pharmacology, University of Montréal

    Internship opportunity(ies)

    No open position


    • Bachelor in Biochemistry, Université de Montpellier (2000)
    • MSc in Biology, Université du Québec à Montréal (2001-2003)
    • PhD in Bbiology, INRS-Institut Armand-Frappier, Université du Québec (2003-2008)
    • Postdoctorat (2009-2013) 
      • MD Anderson Cancer Center, Department of Leukemia, University of Texas
      • Fels Institute for Cancer Research and Molecular Biology, Temple University

    Lab research interests

    • Study of new epigenetic drug mechanism of action in pediatric cancers
    • Study of epigenetic mechanisms controlling histone acetylation
    • Screening of new combinations of epigenetic drugs
    • Discovery of new classes of anti-cancer agents
    • Phase I / II clinical study on the combination of decitabine and genistein

    Lab members

    • Research Assistant: Annie Beaudry, BSc 
    • Doctoral Student: Elodie Da Costa 
    • Masters Student: Gregory Armaos 
    • Masters Student: Simon Jacques-Ricard 
    • Clinical Project Manager: Anne-Julie Landry, MSc, DESS 
    • Clinical Research Coordinator: Ernestine Chablis, MSc, CCRP

    Former members

    • Catherine Thall-Dubé (MSc in Clinical Pharmacology)

    Selected Publications

    • Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill D, Issa J-P. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Research. 2015 [Epub ahead of print] 
    • Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. Journal of National Cancer Institute. 2015 Nov 13;108(2).
    • Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP. Epigenetic synergy between decitabine and platinum derivatives. Clinical Epigenetics. 2015 Sep 11;7(1):97. 
    • Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics. 2015 10(9):872-81. 
    • Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, Mani SA, Issa JP. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biology 2013 Dec 24;14(12):R144. 
    • Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Research 2012 Mar 1;72(5):1170-81. 
    • Spannhoff A, Kim YK, Raynal NJ, Gharibyan V, Su MB, Zhou YY, Li J, Castellano S, Sbardella G, Issa JP, Bedford MT. Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. EMBO Reports 2011 Mar;12(3):238-43.
    • Raynal NJ, Momparler LF, Rivard GE, Momparler RL. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leukemia Research 2011 Jan;35(1):110-8. 
    • Raynal NJ, Charbonneau M, Momparler LF, Momparler RL. Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia. Oncology Research 2008;17(5):223-30. 
    • Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer. 2008 May 2;8:128. 
    • Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemotherapy Pharmacology 2009 Feb;63(3):411-6. 
    • Raynal NJ, Momparler L, Charbonneau M, Momparler RL. Antileukemic activity of genistein, a major isoflavone present in soy products. Journal of Natural Products 2008 Jan;71(1):3-7.
About this page
Edited by Hoffmann Maude

Created on 9/18/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security


Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine